Literature DB >> 24756190

[Pseudotumor cerebri syndrome].

K Rüther1.   

Abstract

Pseudotumor cerebri is a non-tumor related idiopathic or secondary intracranial hypertension. It is typically associated with papilledema and headache and patients are typically female, young and obese. Diagnosis is established by neuroimaging by magnetic resonance imaging (MRI), cerebral MR venography (MRV) and lumbar puncture. Papilledema is assessed by ophthalmoscopy, ultrasound and optical coherence tomography. Ophthalmologists monitor visual function by measuring visual acuity and visual field testing. Therapy of patients not facing immediate visual loss encompasses weight reduction and administration of carbonic anhydrase inhibitors. In vision-threatening situations invasive procedures are necessary, such as repeated lumbar puncture, liquor drainage, optic nerve sheath fenestration and endovascular venous stenting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24756190     DOI: 10.1007/s00347-014-3055-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  21 in total

1.  Fulminant idiopathic intracranial hypertension.

Authors:  Madhav Thambisetty; Patrick J Lavin; Nancy J Newman; Valérie Biousse
Journal:  Neurology       Date:  2007-01-16       Impact factor: 9.910

Review 2.  Cerebral venous sinus system and stenting in pseudotumor cerebri.

Authors:  Matthew J Dykhuizen; Jennifer Hall
Journal:  Curr Opin Ophthalmol       Date:  2011-11       Impact factor: 3.761

Review 3.  Idiopathic intracranial hypertension: a unifying neuroendocrine hypothesis through the adrenal-brain axis.

Authors:  Vincenzo Salpietro; Agata Polizzi; Luca Francesco Bertè; Roberto Chimenz; Valeria Chirico; Sara Manti; Valeria Ferraù; Annamaria Salpietro; Teresa Arrigo; Martino Ruggieri
Journal:  Neuro Endocrinol Lett       Date:  2012       Impact factor: 0.765

4.  Effect of optic nerve sheath fenestration on papilledema of the operated and the contralateral nonoperated eyes in idiopathic intracranial hypertension.

Authors:  Adel H Alsuhaibani; Keith D Carter; Jeffrey A Nerad; Andrew G Lee
Journal:  Ophthalmology       Date:  2011-02       Impact factor: 12.079

Review 5.  An update on idiopathic intracranial hypertension.

Authors:  Matthew J Thurtell; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2010 Spring-Summer

6.  Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.

Authors:  Alexandra J Sinclair; Michael A Burdon; Peter G Nightingale; Alexandra K Ball; Peter Good; Timothy D Matthews; Andrew Jacks; Mark Lawden; Carl E Clarke; Paul M Stewart; Elizabeth A Walker; Jeremy W Tomlinson; Saaeha Rauz
Journal:  BMJ       Date:  2010-07-07

Review 7.  Bariatric surgery for the treatment of idiopathic intracranial hypertension.

Authors:  Jared Fridley; Rod Foroozan; Vadim Sherman; Mary L Brandt; Daniel Yoshor
Journal:  J Neurosurg       Date:  2010-01-22       Impact factor: 5.115

8.  Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.

Authors:  Deborah I Friedman; Grant T Liu; Kathleen B Digre
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

Review 9.  Idiopathic intracranial hypertension (pseudotumor cerebri).

Authors:  Michael Wall
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

10.  The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana.

Authors:  F J Durcan; J J Corbett; M Wall
Journal:  Arch Neurol       Date:  1988-08
View more
  2 in total

1.  [Intracranial hypertension and jugular vein thrombosis].

Authors:  J Konrad; R Vogt; H Helbig; I Oberacher-Velten
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

Review 2.  [Ophthalmological symptoms of idiopathic intracranial hypertension: Importance for diagnosis and clinical course].

Authors:  R Unsöld
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.